OCA
INSM icon

Octagon Capital Advisors’s Insmed INSM Stock Holding History

Octagon Capital Advisors’s Portfolio INSM Stock Details INSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-332,000
Closed -$22.9M – 39
2024
Q4 		$22.9M Sell
332,000
-104,820
-24% -$7.55M 3.77% 7
2024
Q3 		$31.9M Sell
436,820
-213,396
-33% -$15.7M 4.96% 7
2024
Q2 		$43.6M Sell
650,216
-489,784
-43% -$19M 6.85% 4
2024
Q1 		$30.9M Sell
1,140,000
-144,000
-11% -$4.03M 3.71% 7
2023
Q4 		$39.8M Hold
1,284,000
– – 6.37% 4
2023
Q3 		$32.4M Buy
1,284,000
+917,000
+250% +$21M 4.98% 7
2023
Q2 		$7.74M Buy
+367,000
New +$6.96M 1.08% 18

Other funds holding INSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Octagon Capital Advisors's INSM Position: Q1 2025 in Review

Octagon Capital Advisors sold out of Insmed (INSM) in Q1 2025, closing a stake of 332,000 shares — an estimated $22.9M sold.

Octagon Capital Advisors first reported a position in INSM in Q2 2023 and held it in 7 quarters. The position peaked at $43.6M in Q2 2024. 441 funds tracked by Wall St. Rank hold INSM as of Q1 2025.

  • Octagon Capital Advisors reported no remaining Insmed position as of Q1 2025 after selling out during the quarter.
  • Octagon Capital Advisors sold 332,000 Insmed shares in Q1 2025, an estimated $22.9M.
  • Octagon Capital Advisors first reported a position in Insmed in Q2 2023 and held it in 7 quarters.
  • Octagon Capital Advisors's Insmed position peaked at $43.6M in Q2 2024.
  • 441 funds tracked by Wall St. Rank held Insmed as of Q1 2025.

Based on Octagon Capital Advisors's 13F filing for Q1 2025, filed 15 May 2025.